TAK

MKT CAP:$53B

Takeda Pharmaceutical Company Limited

Market Cap

$53B

Healthcare·Drug Manufacturers - Specialty & Generic·🇯🇵 Japan·NYSE

Healthcare·Drug·🇯🇵·NYSE

Stock Price

$16.68+$1.06 (+6.75%)

Apr 24, 2026

Company Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internati...

CEO

Christophe Weber

IPO Date

Jan 5, 2010

Website

www.takeda.com

Key Metrics TTM

Revenue

$28.3B

-0.6% YoY

Net Income

$942M

EPS (Diluted)

$0.29

Free Cash Flow

$6.1B

Revenue / Share

$8.83

Gross Margin

61.6%

Operating Margin

8.2%

Net Margin

3.3%

FCF Margin

21.5%

P/S

1.9x

P/E

55.8x

Earnings Reports

Q4 2025

May 14, 2026

PENDING

Q3 2025

Jan 29, 2026

$7.6B+6.0%EPS $0.21

Q1 2025

Jul 30, 2025

$6.9B-8.4%EPS $0.25

FY 2024

Jun 25, 2025

$28.7B+7.5%EPS $0.21

Q4 2024

Jun 25, 2025

$6.6B+0.2%EPS -$0.20

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 21	$5.6B	$3.9B	$730M
Q4 21	$5.5B	$3.5B	-$10M
Q1 22	$6.1B	$4.3B	$943M
Q2 22	$6.3B	$4.4B	$654M
Q3 22	$6.9B	$4.8B	$921M
Q4 22	$6.0B	$4.0B	$555M
Q1 23	$6.6B	$4.6B	$1.1B
Q2 23	$6.5B	$4.4B	-$309M
Q3 23	$7.0B	$4.6B	$657M
Q4 23	$6.6B	$4.2B	-$63M
Q1 24	$7.6B	$5.1B	$1.0B
Q2 24	$7.4B	$4.9B	$1.2B
Q3 24	$7.2B	$4.6B	$419M
Q4 24	$6.6B	$4.2B	-$469M
Q1 25	$6.9B	$4.5B	$1.2B
Q3 25	$7.6B	$4.1B	$1.2B

Valuation

Quarter	P/S	P/E
Q3 21	2.0x	15.6x
Q4 21	2.0x	31.3x
Q1 22	1.9x	35.1x
Q2 22	1.7x	30.4x
Q3 22	2.0x	28.1x
Q4 22	2.0x	25.9x
Q1 23	1.9x	25.9x
Q2 23	1.8x	39.9x
Q3 23	1.8x	41.7x
Q4 23	1.6x	47.5x
Q1 24	1.5x	43.8x
Q2 24	1.6x	24.8x
Q3 24	1.5x	32.0x
Q4 24	1.6x	69.7x
Q1 25	1.7x	57.1x
Q3 25	1.8x	52.8x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 21	$2.2B	$1.9B
Q4 21	$2.4B	$2.0B
Q1 22	$528M	-$89M
Q2 22	$1.4B	$1.1B
Q3 22	$2.4B	$2.1B
Q4 22	$1.8B	-$942M
Q1 23	$579M	-$1.1B
Q2 23	$1.2B	$807M
Q3 23	$918M	$434M
Q4 23	$1.7B	$1.5B
Q1 24	$1.1B	$707M
Q2 24	$1.8B	$1.5B
Q3 24	$2.4B	$2.1B
Q4 24	$1.4B	$1.1B
Q1 25	$1.3B	$879M
Q3 25	$2.3B	$2.0B

Capital Expenditures

Quarter	CapEx
Q3 21	$303M
Q4 21	$325M
Q1 22	$616M
Q2 22	$254M
Q3 22	$317M
Q4 22	$2.8B
Q1 23	$1.7B
Q2 23	$439M
Q3 23	$483M
Q4 23	$279M
Q1 24	$360M
Q2 24	$310M
Q3 24	$282M
Q4 24	$306M
Q1 25	$470M
Q3 25	$267M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 21	+7.7%	+13.1%
Q4 21	+13.4%	+41.2%
Q1 22	+2.4%	+17.2%
Q2 22	+18.6%	+20.1%
Q3 22	+21.7%	+21.0%
Q4 22	+9.5%	-0.8%
Q1 23	+8.9%	+8.3%
Q2 23	+4.1%	+21.7%
Q3 23	+1.3%	+6.0%
Q4 23	+9.9%	+22.3%
Q1 24	+14.1%	+17.0%
Q2 24	+12.7%	-9.2%
Q3 24	+3.0%	+7.0%
Q4 24	+0.2%	+6.3%
Q1 25	-8.4%	-11.5%
Q3 25	+3.2%	+2.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 21	$69M	1.2%
Q4 21	$71M	1.3%
Q1 22	$77M	1.3%
Q2 22	$107M	1.7%
Q3 22	$103M	1.5%
Q4 22	$93M	1.6%
Q1 23	$97M	1.5%
Q2 23	$116M	1.8%
Q3 23	$117M	1.7%
Q4 23	$114M	1.7%
Q1 24	$96M	1.3%
Q2 24	$0	0.0%
Q3 24	$115M	1.6%
Q4 24	$110M	1.7%
Q1 25	$104M	1.5%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q3 21	$804M	$1.4B
Q4 21	$900M	$1.4B
Q1 22	$900M	$1.5B
Q2 22	$966M	$1.6B
Q3 22	$1.1B	$1.6B
Q4 22	$1.0B	$1.6B
Q1 23	$1.0B	$1.6B
Q2 23	$1.2B	$1.6B
Q3 23	$1.2B	$1.7B
Q4 23	$1.2B	$1.8B
Q1 24	$1.1B	$1.7B
Q2 24	$1.1B	$1.7B
Q3 24	$1.1B	$1.7B
Q4 24	$1.4B	$1.9B
Q1 25	$901M	$1.6B
Q3 25	$1.1B	$1.8B

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$5.3B	$159M	$5.5B
Q1 22	$4.0B	$116M	$4.2B
Q2 22	$5.0B	$200M	$5.2B
Q3 22	$4.3B	$260M	$4.6B
Q4 22	$3.3B	$126M	$3.5B
Q1 23	$2.0B	$327M	$2.3B
Q2 23	$2.0B	$99M	$2.1B
Q3 23	$1.8B	$182M	$2.0B
Q4 23	$2.9B	$95M	$3.0B
Q1 24	$5.0B	$334M	$5.4B
Q2 24	$5.4B	$296M	$5.7B
Q3 24	$3.1B	$204M	$3.3B
Q4 24	$2.4B	$128M	$2.5B
Q1 25	$2.2B	$433M	$2.6B
Q2 25	$4.3B	$365M	$4.6B
Q3 25	$4.1B	$670M	$4.8B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 21	3.15B	-0.3%	-0.0%
Q4 21	3.15B	+0.1%	+0.1%
Q1 22	3.11B	-1.4%	+0.0%
Q2 22	3.13B	+0.6%	-1.1%
Q3 22	3.14B	+0.4%	-0.3%
Q4 22	3.23B	+2.8%	+2.4%
Q1 23	3.13B	-3.0%	+0.7%
Q2 23	3.13B	+0.0%	+0.1%
Q3 23	3.17B	+1.3%	+0.9%
Q4 23	3.14B	-1.0%	-2.8%
Q1 24	3.18B	+1.3%	+1.5%
Q2 24	3.22B	+1.3%	+2.9%
Q3 24	3.17B	-1.6%	-0.0%
Q4 24	3.16B	-0.2%	+0.8%
Q1 25	3.18B	+0.4%	-0.1%
Q3 25	3.20B	+0.9%	-0.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 21	$120.1K	47K
Q4 21	$116.4K	47K
Q1 22	$129.6K	47K
Q2 22	$133.6K	47K
Q3 22	$146.2K	47K
Q4 22	$122.3K	49K
Q1 23	$135.4K	49K
Q2 23	$133.4K	49K
Q3 23	$142.1K	49K
Q4 23	$134.4K	49K
Q1 24	$154.5K	49K
Q2 24	$150.4K	49K
Q3 24	$146.3K	49K
Q4 24	$140.4K	47K
Q1 25	$147.5K	47K
Q3 25	$161.7K	47K

Revenue / Employee